Predicting Immunotherapy Response in Bladder Cancer

ROBERT DREICER, MD

Thursday, March 21, 2019

When it comes to predicting response to checkpoint inhibitors for patients with urothelial carcinoma, PD-L1 status may not be the most accurate factor, explained Robert Dreicer, MD, deputy director of UVA Cancer Center, director of solid tumor oncology within the division of hematology/oncology and is a professor of medicine and urology at the University of Virginia.

PD-L1 is not the most reliable predictor because there are many patients whose tumors are not PD-L1 positive who still respond to immunotherapy. More research in this field is still warranted.

Discussions >>

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.

Related Videos

Challenges and Hopes for Liquid Biopsies in Bladder Cancer

By: Cristina Magi-Galluzzi, MD, PhD

It Takes a Team: Treating Adverse Events

By: Matthew A. Gubens, MD

Risks Versus Benefits in Combining Immunotherapies

By: Ryan J. Sullivan, MD